View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Jul. 12, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Flex Pharma, Inc.
Entity Central Index Key	0001615219
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		18,069,476
Entity Current Reporting Status	Yes
Entity Shell Company	false

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,514,215	$ 9,829,624
Restricted cash	0	126,595
Accounts receivable	28,278	9,939
Inventory	130,920	186,920
Prepaid expenses and other current assets	435,972	162,088
Total current assets	7,109,385	10,315,166
Property and equipment, net	27,954	74,460
Total assets	7,137,339	10,389,626
Current liabilities:
Accounts payable	805,516	342,530
Accrued expenses and other current liabilities	230,752	764,340
Total current liabilities	1,036,268	1,106,870
Total liabilities	1,036,268	1,106,870
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2019 and December 31, 2018; none issued or outstanding at June 30, 2019 and December 31, 2018	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized at June 30, 2019 and December 31, 2018; 18,069,476 and 18,069,476 shares issued at June 30, 2019 and December 31, 2018, and 18,068,642 and 18,067,392 shares outstanding at June 30, 2019 and December 31, 2018, respectively	1,807	1,807
Additional paid-in capital	142,675,746	142,242,224
Accumulated deficit	(136,576,482)	(132,961,275)
Total stockholders' equity	6,101,071	9,282,756
Total liabilities and stockholders' equity	$ 7,137,339	$ 10,389,626

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (shares)	10,000,000	10,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (shares)	100,000,000	100,000,000
Common stock, shares issued (shares)	18,069,476	18,069,476
Common stock, shares outstanding (shares)	18,068,642	18,067,392

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 164,705	$ 245,502	$ 269,682	$ 424,084
Costs and expenses:
Cost of product revenue	36,148	179,945	83,477	263,879
Research and development	29,294	6,174,589	31,000	10,854,770
Selling, general and administrative	1,497,401	2,994,649	3,796,986	6,691,936
Total costs and expenses	1,562,843	9,349,183	3,911,463	17,810,585
Loss from operations	(1,398,138)	(9,103,681)	(3,641,781)	(17,386,501)
Interest income, net	13,361	51,809	26,574	111,402
Net loss	(1,384,777)	(9,051,872)	(3,615,207)	(17,275,099)
Net loss attributable to common stockholders	$ (1,384,777)	$ (9,051,872)	$ (3,615,207)	$ (17,275,099)
Net loss per share attributable to common stockholders - basic and diluted (in usd per share)	$ (0.08)	$ (0.50)	$ (0.20)	$ (0.96)
Weighted-average number of common shares outstanding — basic and diluted (shares)	18,068,429	18,037,274	18,068,120	17,965,989
Net product revenue
Total revenue	$ 163,071	$ 241,416	$ 267,291	$ 417,671
Other revenue
Total revenue	$ 1,634	$ 4,086	$ 2,391	$ 6,413

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (1,384,777)	$ (9,051,872)	$ (3,615,207)	$ (17,275,099)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	0	(93)	0	1,247
Comprehensive loss	$ (1,384,777)	$ (9,051,965)	$ (3,615,207)	$ (17,273,852)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities
Net loss	$ (3,615,207)	$ (17,275,099)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	46,506	124,000
Stock-based compensation expense	433,522	1,419,933
Amortization and accretion on investments	0	11,537
Other non-cash items	0	22,274
Changes in operating assets and liabilities:
Accounts receivable	(18,339)	(184)
Inventory	56,000	139,206
Prepaid expenses and other current assets	(273,884)	(93,909)
Accounts payable	462,986	(859,107)
Accrued expenses and other current liabilities	(533,588)	(1,127,164)
Deferred rent	0	(29,410)
Net cash used in operating activities	(3,442,004)	(17,667,923)
Investing activities
Purchases of marketable securities	0	(1,997,751)
Proceeds from maturities and sales of marketable securities	0	16,117,184
Proceeds from sales of property and equipment	0	1,415
Net cash provided by investing activities	0	14,120,848
Financing activities
Proceeds from exercise of common stock	0	118,010
Net cash provided by financing activities	0	118,010
Net decrease in cash, cash equivalents and restricted cash	(3,442,004)	(3,429,065)
Cash, cash equivalents and restricted cash at beginning of period	9,956,219	19,312,631
Cash, cash equivalents and restricted cash at end of period	$ 6,514,215	$ 15,883,566

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Preferred stock, beginning balance (shares) at Dec. 31, 2017		0
Equity, beginning balance at Dec. 31, 2017	$ 29,105,888	$ 0	$ 1,780	$ 140,184,630	$ (1,247)	$ (111,079,275)
Common stock, beginning balance (shares) at Dec. 31, 2017			17,797,178
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (shares)			171,029
Vesting of restricted common stock	0		$ 17	(17)
Issuance of common stock from option exercises (shares)			12,645
Issuance of common stock from option exercises	54,913		$ 1	54,912
Stock-based compensation expense	908,940			908,940
Unrealized gain (loss) on available-for-sale securities	1,340				1,340
Net loss	(8,223,227)					(8,223,227)
Preferred stock, ending balance (shares) at Mar. 31, 2018		0
Equity, ending balance at Mar. 31, 2018	21,888,071	$ 0	$ 1,798	141,148,465	93	(119,262,285)
Common stock, ending balance (shares) at Mar. 31, 2018			17,980,852
Preferred stock, beginning balance (shares) at Dec. 31, 2017		0
Equity, beginning balance at Dec. 31, 2017	29,105,888	$ 0	$ 1,780	140,184,630	(1,247)	(111,079,275)
Common stock, beginning balance (shares) at Dec. 31, 2017			17,797,178
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain (loss) on available-for-sale securities	1,247
Net loss	(17,275,099)
Preferred stock, ending balance (shares) at Jun. 30, 2018		0
Equity, ending balance at Jun. 30, 2018	13,410,196	$ 0	$ 1,807	141,722,546	0	(128,314,157)
Common stock, ending balance (shares) at Jun. 30, 2018			18,066,142
Preferred stock, beginning balance (shares) at Mar. 31, 2018		0
Equity, beginning balance at Mar. 31, 2018	21,888,071	$ 0	$ 1,798	141,148,465	93	(119,262,285)
Common stock, beginning balance (shares) at Mar. 31, 2018			17,980,852
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (shares)			625
Vesting of restricted common stock	0
Issuance of common stock from option exercises (shares)			84,665
Issuance of common stock from option exercises	63,097		$ 9	63,088
Stock-based compensation expense	510,993			510,993
Unrealized gain (loss) on available-for-sale securities	(93)				(93)
Net loss	(9,051,872)					(9,051,872)
Preferred stock, ending balance (shares) at Jun. 30, 2018		0
Equity, ending balance at Jun. 30, 2018	$ 13,410,196	$ 0	$ 1,807	141,722,546	0	(128,314,157)
Common stock, ending balance (shares) at Jun. 30, 2018			18,066,142
Preferred stock, beginning balance (shares) at Dec. 31, 2018	0	0
Equity, beginning balance at Dec. 31, 2018	$ 9,282,756	$ 0	$ 1,807	142,242,224	0	(132,961,275)
Common stock, beginning balance (shares) at Dec. 31, 2018	18,067,392		18,067,392
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (shares)			625
Vesting of restricted common stock	$ 0
Stock-based compensation expense	220,975			220,975
Net loss	(2,230,430)					(2,230,430)
Preferred stock, ending balance (shares) at Mar. 31, 2019		0
Equity, ending balance at Mar. 31, 2019	$ 7,273,301	$ 0	$ 1,807	142,463,199	0	(135,191,705)
Common stock, ending balance (shares) at Mar. 31, 2019			18,068,017
Preferred stock, beginning balance (shares) at Dec. 31, 2018	0	0
Equity, beginning balance at Dec. 31, 2018	$ 9,282,756	$ 0	$ 1,807	142,242,224	0	(132,961,275)
Common stock, beginning balance (shares) at Dec. 31, 2018	18,067,392		18,067,392
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from option exercises (shares)	0
Unrealized gain (loss) on available-for-sale securities	$ 0
Net loss	$ (3,615,207)
Preferred stock, ending balance (shares) at Jun. 30, 2019	0	0
Equity, ending balance at Jun. 30, 2019	$ 6,101,071	$ 0	$ 1,807	142,675,746	0	(136,576,482)
Common stock, ending balance (shares) at Jun. 30, 2019	18,068,642		18,068,642
Preferred stock, beginning balance (shares) at Mar. 31, 2019		0
Equity, beginning balance at Mar. 31, 2019	$ 7,273,301	$ 0	$ 1,807	142,463,199	0	(135,191,705)
Common stock, beginning balance (shares) at Mar. 31, 2019			18,068,017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (shares)			625
Vesting of restricted common stock	0
Stock-based compensation expense	212,547			212,547
Unrealized gain (loss) on available-for-sale securities	0
Net loss	$ (1,384,777)					(1,384,777)
Preferred stock, ending balance (shares) at Jun. 30, 2019	0	0
Equity, ending balance at Jun. 30, 2019	$ 6,101,071	$ 0	$ 1,807	$ 142,675,746	$ 0	$ (136,576,482)
Common stock, ending balance (shares) at Jun. 30, 2019	18,068,642		18,068,642

Organization and operations	6 Months Ended
Organization and operations	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and operations	Organization and operations The Company Flex Pharma Inc., or the Company, is a biotechnology company that was previously focused on developing innovative and proprietary treatments for muscle cramps, spasms and spasticity associated with severe neurological conditions. In June 2018, the Company announced that it was ending its ongoing Phase 2 clinical trials of its lead drug product candidate, FLX-787, in patients with motor neuron disease, or MND, primarily with amyotrophic lateral sclerosis, or ALS, and in patients with Charcot-Marie-Tooth disease, or CMT, due to oral tolerability concerns observed in both studies. The wind-down of the activities associated with these studies was completed in the third quarter of 2018. In 2016, the Company launched its consumer product, HOTSHOT®, to prevent and treat exercise-associated muscle cramps, or EAMCs. The Company continues to market and sell HOTSHOT to endurance athletes who drink it before, during and after exercise to prevent and treat EAMCs. In June 2018, the Company initiated a process to explore a range of strategic alternatives for enhancing stockholder value, including the potential sale or merger of the Company. Following an extensive process of evaluating strategic alternatives for the Company, on January 3, 2019, the Company entered into an Agreement and Plan of Merger, or the Merger Agreement, with Salarius Pharmaceuticals, LLC, or Salarius, under which the privately held Salarius will merge with a wholly owned subsidiary of the Company. At a special meeting on July 12, 2019, the merger was approved by the Company's stockholders and the merger is expected to close on or about July 19, 2019. Upon completion of the merger, the business of Salarius will continue as the business of the combined company. The Company operates as two reportable segments, Consumer Operations and Drug Development. See Note 12 for additional discussion and information on the reportable segments. Liquidity The Company incurred a loss of $1,384,777 for the three months ended June 30, 2019, a loss of $3,615,207 for the six months ended June 30, 2019 and had an accumulated deficit of $136,576,482 as of June 30, 2019. The Company had unrestricted cash and cash equivalents of $6,514,215 at June 30, 2019. The Company's operating plan assumes limited research and development activities and that the Consumer Operations segment will continue to sell HOTSHOT. In the event the merger with Salarius is not completed, the Company will reconsider its strategic alternatives, including to (i) pursue a dissolution and liquidation of the Company, (ii) pursue another strategic transaction or (iii) continue to market HOTSHOT and operate its consumer business. If the Company dissolves and liquidates, the Company's common stockholders may lose their entire investment. The amount of assets available for distribution to the Company's stockholders would depend heavily on the timing of such liquidation as well as the amount of cash that would be needed for commitments and contingent liabilities. Based on the Company's current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to allow the Company to fund its current operating plan for at least 12 months from the date the financial statements are issued. The Company cannot predict the outcome of the merger or whether and to what extent it will resume drug development activities and to what extent it will promote and sell HOTSHOT or other consumer products in the future. Accordingly, it is difficult to predict future cash needs. Management does expect the Company to continue to incur losses for the foreseeable future. The Company's ability to achieve profitability in the future is dependent upon achieving a level of revenues adequate to support the Company's cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. If the Company raises funds through the sale of equity or convertible debt securities, the issuance of those securities could result in substantial dilution of the stockholders' ownership in the Company. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, or at all.

Summary of significant accounting policies and recent accounting pronouncements	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies and recent accounting pronouncements	Summary of significant accounting policies and recent accounting pronouncements The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the condensed consolidated financial statements. As of June 30, 2019, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 10-K”), have not changed, other than as noted below. Accounts receivable and allowance for doubtful accounts Accounts receivable are stated at their carrying values, net of any allowances for doubtful accounts. Accounts receivable consist primarily of amounts due from specialty retailers and sports teams, for which collection is probable based on the customer's intent and ability to pay. Receivables are evaluated for collection probability on a regular basis and an allowance for doubtful accounts is recorded, if necessary. No allowance for doubtful accounts was deemed necessary at June 30, 2019 or December 31, 2018. Restricted cash As of December 31, 2018, the Company had restricted cash in the form of a letter of credit it maintained as a security deposit on the lease of its former corporate headquarters in Boston, Massachusetts that was set to expire on August 31, 2019. The Company terminated this lease on December 13, 2018. The letter of credit was released, and the cash became unrestricted on January 4, 2019. Advertising expense Advertising expense consists of media and production costs related to print and digital advertising. All advertising is expensed as incurred. Total advertising expenses are included in selling, general and administrative expenses in the condensed consolidated statement of operations, and were approximately $8,000 and $18,000 for the three and six months ended June 30, 2019 and approximately $264,000 and $772,000 for the three and six months ended June 30, 2018. Shipping and handling costs Shipping and handling costs related to the movement of inventory to the Company's co-packer and from the co-packer to the Company's third-party warehousing and fulfillment partners are capitalized as inventory and expensed as cost of product revenue when revenue is recognized. Shipping and handling costs to move finished goods from the Company's third-party warehousing and fulfillment partners to customer locations are included in selling, general and administrative expenses in the condensed consolidated statement of operations, and were approximately $20,000 and $35,000 for the three and six months ended June 30, 2019, and approximately $29,000 and $54,000 for the three and six months ended June 30, 2018. Restructuring-related costs The Company records employee termination costs in accordance with Accounting Standards Codification ("ASC") Topic 712, Compensation - Nonretirement and Postemployment Benefits ("ASC 712"), if the termination benefits are paid as part of an ongoing benefit arrangement, which includes benefits provided as part of the Company's established severance policy or as part of an executive employment agreement. The Company accrues employee termination costs associated with an on-going benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable, and the Company can reasonably estimate the liability. The Company accounts for employee termination benefits that represent a one-time benefit in accordance with ASC Topic 420, Exit or Disposal Cost Obligations ("ASC 420"). Upon communication of the termination to the employee, the Company expenses these costs over the employee’s future service period, if any. Restructuring-related costs are recorded within research and development expenses and selling, general and administrative expenses on the Company's consolidated statement of operations. Liabilities associated with the Company's restructuring activities are recorded as a component of accrued expenses and other current liabilities on its consolidated balance sheets. See Note 7 for additional information on the Company's current restructuring plan. Unaudited interim financial information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the 2018 10-K. The condensed consolidated financial statements as of June 30, 2019, for the three and six months ended June 30, 2019 and 2018, and the related information contained within the notes to the condensed consolidated financial statements, are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as annual audited consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of June 30, 2019, and the statements of operations, comprehensive loss, cash flows and stockholders' equity for the three and six month periods ended June 30, 2019 and 2018. The results for the three and six months ended June 30, 2019 are not necessarily indicative of results to be expected for the year ending December 31, 2019, or any other future annual or interim periods. Basis of presentation and use of estimates The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: TK Pharma, Inc., a Massachusetts Securities Corporation, Flex Innovation Group LLC, a Delaware limited liability company which contains the Company's consumer-related operations, and Falcon Acquisition Sub, LLC, a Delaware limited liability company established for purposes of the merger. All significant intercompany balances and transactions have been eliminated in consolidation. Recent accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The ASU requires lessees to recognize the assets and liabilities on their balance sheet for the rights and obligations created by most leases and continue to recognize expenses on their income statements over the lease term. It also requires disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising from leases. The guidance is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. The Company adopted ASU No. 2016-02 in the first quarter of 2019, which did not materially impact the Company's condensed consolidated financial statements or disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The guidance is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact of ASU No. 2018-13 on its consolidated financial statements and disclosures. The Company believes that the impact of other recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption.

Revenue from contracts with customers

6 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue from contracts with customers

Revenue recognition

Revenue includes sales of HOTSHOT bottled finished goods to e-commerce customers, specialty retailers and sports teams, including professional and amateur teams. Revenue also consists of payments made by customers for expedited shipping and handling.

The Company expenses fulfillment costs as incurred because the amortization period would be less than one year in accordance with the ASC 606, Revenue from Contracts with Customers ("ASC 606"), practical expedient.

In accordance with ASC 606, the Company applies the following steps to recognize revenue for the sale of bottled finished goods that reflects the consideration to which the Company expects to be entitled to receive in exchange for the promised goods:


1.	Identify the contract with a customer

A contract with a customer exists when the Company enters into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers, or the execution of terms and conditions contracts with specialty retailers and sports teams. These contracts define each party's rights, payment terms and other contractual terms and conditions of the sale. The Company applies judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience and, in some circumstances, published credit and financial information pertaining to the customer.


2.	Identify the performance obligations in the contract

Performance obligations promised in a contract are identified based on the goods that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. The Company has concluded the sale of bottled finished goods and related shipping and handling are accounted for as a single performance obligation.


3.	Determine the transaction price

The transaction price is determined based on the consideration to which the Company will be entitled to receive in exchange for transferring goods to the customer. For sales through June 18, 2018, the Company offered refunds to e-commerce customers, upon request, within 30 days of delivery. For sales subsequent to June 18, 2018, the Company now offers refunds to e-commerce customers, upon request, within 14 days of delivery. The Company estimates the amount of potential refunds at each reporting period using a portfolio approach of historical data, adjusted for changes in expected customer experience, including seasonality and changes in economic factors, as necessary. For specialty retailers and sports teams, the Company does not offer a right of return or refund and revenue is recognized at the time products are delivered to customers.

Discounts provided to customers are accounted for as an element of the transaction price and as a reduction to revenue, and were approximately $1,000 and $2,000 for the three and six months ended June 30, 2019, respectively, and approximately $9,000 and $17,000 for the three and six months ended June 30, 2018, respectively.

Revenue is presented net of taxes collected from customers and remitted to governmental authorities.


4.	Determine the satisfaction of performance obligation

Revenue is recognized when control of the bottled finished goods is transferred to the customer. Control of the bottled finished goods is transferred at a point in time, upon delivery to the customer. The period of time between the satisfaction of the performance obligation and when payment is due from the customer is not significant.

Concentrations of credit risk

The Company had no customers that represented greater than 10% of total revenue during the three and six months ended June 30, 2019 or the three and six months ended June 30, 2018. All of the Company's revenue was generated from sales within the United States.

Fair value measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair value measurements

The Company records cash equivalents at fair value. ASC Topic 820, Fair Value Measurements and Disclosures, established a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The following tables summarize the cash equivalents measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:



	Level 1		Level 2		Level 3		Balance as of June 30, 2019
Cash equivalents	$	2,360,092	$	—	$	—	$	2,360,092
	$	2,360,092	$	—	$	—	$	2,360,092



	Level 1		Level 2		Level 3		Balance as of December 31, 2018
Cash equivalents	$	2,333,771	$	—	$	—	$	2,333,771
	$	2,333,771	$	—	$	—	$	2,333,771

Cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The third-party pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. The Company's cash equivalents consist of money market funds that are valued based on publicly available quoted market prices for identical securities as of June 30, 2019. After completing its validation procedures, the Company did not adjust or override any fair value carrying amounts as of June 30, 2019.

The carrying amounts reflected in the condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values at June 30, 2019 and December 31, 2018, due to their short-term nature.

The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1 and Level 2 during the six months ended June 30, 2019 or the year ended December 31, 2018. The Company had no financial assets or liabilities that were classified as Level 3 at any time during the six months ended June 30, 2019 or the year ended December 31, 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash equivalents

6 Months Ended

Jun. 30, 2019

Cash and Cash Equivalents [Abstract]

Cash equivalents

The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash equivalents as of June 30, 2019 and December 31, 2018 consisted of money market funds.

The Company held no marketable securities at June 30, 2019 and December 31, 2018.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of such amounts in the condensed consolidated statements of cash flows:



	June 30, 2019		December 31, 2018
Cash and cash equivalents	$	6,514,215	$	9,829,624
Restricted cash	—		126,595
Cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	6,514,215	$	9,956,219

Inventory

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Inventory

Inventory has been recorded at cost as of June 30, 2019 and December 31, 2018. Costs capitalized at June 30, 2019 and December 31, 2018 relate to HOTSHOT finished goods, as well as raw materials available to be used for future production runs.

The following table presents inventory:



	June 30, 2019		December 31, 2018
Raw materials	$	7,247	$	7,247
Finished goods	123,673		179,673
Total inventory	$	130,920	$	186,920

There were no inventory write-offs during the three and six months ended June 30, 2019. Write-offs totaled approximately $85,000 for the three and six months ended June 30, 2018, and were included in cost of product revenue in the accompanying condensed consolidated statement of operations. In the second quarter of 2018, the Company wrote off raw materials that were not expected to be used in future production runs, as well as finished goods inventory no longer expected to be used for product sampling.

Accrued expenses and other current liabilities

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following:



	June 30, 2019		December 31, 2018
Professional fees	$	171,474	$	269,544
Payroll and other employee-related costs	48,797		417,997
Consumer product-related costs	10,481		5,360
Restructuring-related costs	—		68,593
Other research and development-related costs	—		2,846
Total	$	230,752	$	764,340

Restructuring-related costs

In June 2018, the Company's Board of Directors, or the Board, approved a corporate restructuring plan to reduce the Company's cost structure. In connection with the corporate restructuring plan, the Company reduced its workforce by approximately 60%, with the reduction completed as of September 30, 2018. As of June 30, 2019, the Company had paid $51,000 in retention bonuses and $889,000 in severance benefits associated with these arrangements.

Also, in June 2018, the Board approved employee retention arrangements and certain increased severance payments related to the corporate restructuring plan, to incentivize certain employees to remain with the Company through a potential sale or merger. As of June 30, 2019, the Company had paid $214,000 in retention bonuses, $410,000 in annual bonuses and $185,000 in severance benefits associated with these arrangements. As of June 30, 2019, cash retention benefits totaling approximately $603,000 will be payable to the remaining employees and certain former employees who continue to provide service as consultants, upon the occurrence of a change in control event, including a sale or merger of the Company. Upon a change in control event and termination without cause, the remaining employees will be eligible for up to approximately $928,000, in the aggregate, of severance benefits.

During the six months ended June 30, 2019, the Company recognized a reduction in the accrual for restructuring-related activities of approximately $11,000, which is composed of approximately $3,000 for one-time termination benefit costs and approximately $8,000 for termination benefits under ongoing benefit arrangements for terminated employees as certain benefit payments are no longer expected to occur. Cumulatively, through June 30, 2019, the Company recognized expense for restructuring-related activities of approximately $1,355,000 which is composed of approximately $1,029,000 of termination benefits under ongoing benefit arrangements for terminated employees, approximately $97,000 as one-time termination benefit costs for terminated employees, approximately $214,000 in retention benefits for seven retained employees who had retention bonuses not triggered by a change in control event and approximately $15,000 of other restructuring related costs including consulting and legal fees.

As of June 30, 2019, the Company’s stockholders had not yet approved the merger with Salarius, and accordingly, there were no assurances a change in control event would take place. As a result, the Company does not consider the payment of severance benefits for retained employees or the payment of retention benefits only payable upon a change in control to be probable for accounting purposes as of June 30, 2019. The Company's probability assessment regarding a change in control event changed on July 12, 2019 when the merger was approved by the Company's stockholders.

The Company expects to incur between approximately $1,765,000 and $3,343,000 in total costs for its restructuring-related activities, including approximately $1,355,000 in termination and retention charges and approximately $410,000 related to the annual bonus program, both of which were recorded between the second quarter of 2018 and the first quarter of 2019. The range noted above includes approximately $928,000 of severance benefits for retained employees upon a change in control event and termination under certain circumstances and $603,000 related to retention benefits only payable upon a change in control event. Upon the Company's stockholders approval of the merger with Salarius at the special meeting on July 12, 2019, the payment of these amounts became probable. The merger is expected to close on or about July 19, 2019, at which time, the remaining termination and retention charges will be paid out.

The following table outlines the Company's restructuring activities for the six months ended June 30, 2019:



Accrued restructuring balance as of December 31, 2018	$	68,593
Adjustments:
Employee termination benefits	(11,228		)
Payments	(57,365		)
Accrued restructuring balance as of June 30, 2019	$	—

During the three months ended June 30, 2019, there were no restructuring charges recorded.

For the six months ended June 30, 2019, the $11,000 of the reduction in the accrual for restructuring-related activities is included in research and development expenses in the Company's condensed consolidated statement of operations. Cumulatively through June 30, 2019, approximately $957,000 of the restructuring-related and annual bonus charges are included in research and development expenses and approximately $808,000 are included in selling, general and administrative expenses.

For the six months ended June 30, 2019, the reduction in the accrual for restructuring-related activities of approximately $11,000 was incurred by the Company's Drug Development segment. Cumulatively through June 30, 2019, approximately $94,000 of the restructuring-related and annual bonus charges were incurred by the Company's Consumer Operations segment, approximately $957,000 were incurred by the Company's Drug Development segment and the remaining charges of approximately $714,000 related to corporate costs. Including approximately $1,765,000 of cumulative costs incurred through June 30, 2019, the Company may incur total restructuring-related charges of up to approximately $114,000 and $1,024,000 within its Consumer Operations and Drug Development segments, respectively. The Company may incur up to $2,205,000 of corporate costs that do not relate to a reportable segment.

Common stock

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Common stock

As of June 30, 2019, the Company had authorized 100,000,000 shares of common stock, $0.0001 par value per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors. The Company does not intend to declare dividends for the foreseeable future.

Restricted common stock to consultants

During 2016, the Company issued 18,194 shares of restricted common stock to non-employee consultants and advisors. Such shares are not accounted for as outstanding until they vest. There were 17,360 shares of restricted common stock issued to consultants outstanding as of June 30, 2019.

The following is a summary of restricted common stock activity:



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2018	2,084		$	11.05
Issued	—		—
Vested	(1,250	)	11.05
Forfeited	—		—
Unvested at June 30, 2019	834		$	11.05

Stock-based compensation

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Stock-based compensation

In March 2014, the Company adopted the Flex Pharma, Inc. 2014 Equity Incentive Plan (the "2014 Plan"), under which it had the ability to grant incentive stock options ("ISOs"), non-qualified stock options, restricted stock awards, restricted stock units and stock appreciation rights. Terms of stock award agreements, including vesting requirements, were determined by the board of directors, subject to the provisions of the 2014 Plan. For options granted under the 2014 Plan, the exercise price equaled the fair market value of the common stock as determined by the board of directors on the date of grant. No further awards will be granted under the 2014 Plan.

In January 2015, the Company's Board adopted, and the Company's stockholders approved, the 2015 Equity Incentive Plan (the "2015 Plan"), which became effective immediately prior to the closing of the Company's initial public offering ("IPO"). The 2015 Plan provides for the grant of ISOs, nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of June 30, 2019, there were 2,487,140 shares remaining available for the grant of stock awards under the 2015 Plan.

The Company has awarded stock options to its employees, directors, advisors and consultants, pursuant to the plans described above. Stock options subsequent to the completion of the Company's IPO were granted with an exercise price equal to the closing market price of the Company's common stock on the date of grant. Stock options generally vest over one to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period.

The following table summarizes stock option activity for employees and non-employees for the six months ended June 30, 2019:



	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2018	2,320,981		$	4.10	7.61	$	—
Granted	—		—
Exercised	—		—
Forfeited	—		—
Expired	(23,945	)	4.41
Outstanding at June 30, 2019	2,297,036		$	4.10	7.11	$	—
Exercisable at June 30, 2019	1,346,425		$	5.11	6.05	$	—
Vested or expected to vest at June 30, 2019	2,297,036		$	4.10	7.11	$	—

Total stock-based compensation expense recognized for employee and non-employee restricted common stock, and stock options granted to employees and non-employees is included in the Company's condensed consolidated statements of operations as follows:



	Three Months Ended June 30, 2019		Three Months Ended June 30, 2018		Six Months Ended June 30, 2019		Six Months Ended June 30, 2018
Research and development	$	19,323	$	244,869	$	38,765	$	631,406
Selling, general and administrative	193,224		266,124		394,757		788,527
Total	$	212,547	$	510,993	$	433,522	$	1,419,933

As of June 30, 2019, there was approximately $1,726,000 of total unrecognized compensation cost related to unvested equity awards. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 2.35 years.

On June 14, 2018, the Company granted 654,544 stock options, in the aggregate, to seven employees as part of the Company's retention arrangements with these employees. These awards vest monthly over 48 months as the employees provide continuous service, and expense is being recognized over this period. The awards are exercisable for one to three-years post termination depending on the employee to which the stock options were granted. The awards vest in full upon a change in control event and termination under certain circumstances. As of June 30, 2019, a change in control event was not considered probable for accounting purposes. The Company's probability assessment regarding a change in control event did not change until the merger with Salarius was approved by the Company's stockholders at a special meeting on July 12, 2019.

Employee stock purchase plan

As of June 30, 2019, no shares of common stock have been purchased under the ESPP.

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Based upon the Company's history of operating losses and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets. There was no significant income tax provision or benefit for the six months ended June 30, 2019 or 2018.

Net loss per share

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Net loss per share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury stock method and the if-converted method, for convertible securities, if inclusion of these is dilutive.

As the Company has reported a net loss for the periods presented, diluted net loss per common share is the same as basic net loss per common share.

The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding for the periods indicated, because including them would have had an anti-dilutive impact:



	June 30, 2019	June 30, 2018
Options to purchase common stock	2,297,036	3,098,813
Unvested restricted common stock	834	3,334
Total	2,297,870	3,102,147

Segment Information

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Segment Information

The Company operates as two reportable segments:


•	The Consumer Operations segment, which reflects the total revenue and costs and expenses related to HOTSHOT and the Company's consumer operations.


•	The Drug Development segment, which reflects the costs and expenses related to the Company's efforts to develop innovative and proprietary drug products; previously to treat muscle cramps, spasms and spasticity associated with severe neurological conditions.

The Company discloses information about its reportable segments based on the way that the Company's Chief Operating Decision Maker, who the Company has identified as the Chief Executive Officer, and management, organizes segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its reportable segments based on revenue and operating income or loss. Although the Company reduced its research and development efforts in connection with its strategic assessment in June 2018, the Company continues to manage and operate as two segments and it is unclear to what extent it may resume research and development activities in the future. The accounting policies of the segments are the same as those described herein as well as those described in Note 2. Corporate and unallocated amounts that do not relate to a reportable segment have been allocated to "Corporate." No asset information has been provided for the Company's reportable segments as management does not measure or allocate such assets on a reportable segment basis.

Information for the Company's reportable segments for the three months ended June 30, 2019 and 2018 are as follows:



Three Months Ended June 30, 2019	Consumer Operations		Drug Development		Corporate		Consolidated
Total revenue	$	164,705	—		—		$	164,705
Interest income, net	$	—	—		13,361		$	13,361
Income (loss) from operations	$	11,821	(29,294	)	(1,380,665	)	$	(1,398,138	)



Three Months Ended June 30, 2018	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	245,502		—		—		$	245,502
Interest income, net	$	—		—		51,809		$	51,809
Loss from operations	$	(645,687	)	(6,170,488	)	(2,287,506	)	$	(9,103,681	)

Information for the Company's reportable segments for the six months ended June 30, 2019 and 2018 are as follows:



Six Months Ended June 30, 2019	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	269,682		—		—		$	269,682
Interest income, net	$	—		—		26,574		$	26,574
Loss from operations	$	(41,287	)	(29,678	)	(3,570,816	)	$	(3,641,781	)



Six Months Ended June 30, 2018	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	424,084		—		—		$	424,084
Interest income, net	$	—		—		111,402		$	111,402
Loss from operations	$	(1,902,993	)	(10,834,565	)	(4,648,943	)	$	(17,386,501	)

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event At a special meeting of the Company's stockholders held on July 12, 2019, the merger with Salarius was approved by the Company's stockholders. The merger is expected to close on or about July 19, 2019.

Summary of significant accounting policies and recent accounting pronouncements (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Accounts receivable	Accounts receivable are stated at their carrying values, net of any allowances for doubtful accounts. Accounts receivable consist primarily of amounts due from specialty retailers and sports teams, for which collection is probable based on the customer's intent and ability to pay.
Allowance for doubtful accounts	Receivables are evaluated for collection probability on a regular basis and an allowance for doubtful accounts is recorded, if necessary.
Restricted cash	As of December 31, 2018, the Company had restricted cash in the form of a letter of credit it maintained as a security deposit on the lease of its former corporate headquarters in Boston, Massachusetts that was set to expire on August 31, 2019. The Company terminated this lease on December 13, 2018. The letter of credit was released, and the cash became unrestricted on January 4, 2019.
Advertising expense	Advertising expense consists of media and production costs related to print and digital advertising. All advertising is expensed as incurred.
Shipping and handling costs	Shipping and handling costs related to the movement of inventory to the Company's co-packer and from the co-packer to the Company's third-party warehousing and fulfillment partners are capitalized as inventory and expensed as cost of product revenue when revenue is recognized. Shipping and handling costs to move finished goods from the Company's third-party warehousing and fulfillment partners to customer locations are included in selling, general and administrative expenses in the condensed consolidated statement of operations
Restructuring-related costs	The Company records employee termination costs in accordance with Accounting Standards Codification ("ASC") Topic 712, Compensation - Nonretirement and Postemployment Benefits ("ASC 712"), if the termination benefits are paid as part of an ongoing benefit arrangement, which includes benefits provided as part of the Company's established severance policy or as part of an executive employment agreement. The Company accrues employee termination costs associated with an on-going benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable, and the Company can reasonably estimate the liability. The Company accounts for employee termination benefits that represent a one-time benefit in accordance with ASC Topic 420, Exit or Disposal Cost Obligations ("ASC 420"). Upon communication of the termination to the employee, the Company expenses these costs over the employee’s future service period, if any. Restructuring-related costs are recorded within research and development expenses and selling, general and administrative expenses on the Company's consolidated statement of operations. Liabilities associated with the Company's restructuring activities are recorded as a component of accrued expenses and other current liabilities on its consolidated balance sheets. See Note 7 for additional information on the Company's current restructuring plan.
Basis of presentation	The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").
Use of estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Principles of consolidation	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: TK Pharma, Inc., a Massachusetts Securities Corporation, Flex Innovation Group LLC, a Delaware limited liability company which contains the Company's consumer-related operations, and Falcon Acquisition Sub, LLC, a Delaware limited liability company established for purposes of the merger. All significant intercompany balances and transactions have been eliminated in consolidation.
Recent accounting pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The ASU requires lessees to recognize the assets and liabilities on their balance sheet for the rights and obligations created by most leases and continue to recognize expenses on their income statements over the lease term. It also requires disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising from leases. The guidance is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. The Company adopted ASU No. 2016-02 in the first quarter of 2019, which did not materially impact the Company's condensed consolidated financial statements or disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The guidance is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact of ASU No. 2018-13 on its consolidated financial statements and disclosures. The Company believes that the impact of other recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption.
Fair value measurements	The Company records cash equivalents at fair value. ASC Topic 820, Fair Value Measurements and Disclosures, established a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.
Cash equivalents	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash equivalents as of June 30, 2019 and December 31, 2018 consisted of money market funds.

Fair value measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Summary Of Cash Equivalents And Marketable Securities Measured At Fair Value On A Recurring Basis

The following tables summarize the cash equivalents measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:



	Level 1		Level 2		Level 3		Balance as of June 30, 2019
Cash equivalents	$	2,360,092	$	—	$	—	$	2,360,092
	$	2,360,092	$	—	$	—	$	2,360,092



	Level 1		Level 2		Level 3		Balance as of December 31, 2018
Cash equivalents	$	2,333,771	$	—	$	—	$	2,333,771
	$	2,333,771	$	—	$	—	$	2,333,771

Cash equivalents (Tables)

6 Months Ended

Jun. 30, 2019

Cash and Cash Equivalents [Abstract]

Restrictions On Cash And Cash Equivalents



	June 30, 2019		December 31, 2018
Cash and cash equivalents	$	6,514,215	$	9,829,624
Restricted cash	—		126,595
Cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	6,514,215	$	9,956,219

Schedule Of Cash And Cash Equivalents



	June 30, 2019		December 31, 2018
Cash and cash equivalents	$	6,514,215	$	9,829,624
Restricted cash	—		126,595
Cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	6,514,215	$	9,956,219

Inventory (Tables)

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventory, Net

The following table presents inventory:



	June 30, 2019		December 31, 2018
Raw materials	$	7,247	$	7,247
Finished goods	123,673		179,673
Total inventory	$	130,920	$	186,920

Accrued expenses and other current liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses and other current liabilities consisted of the following:



	June 30, 2019		December 31, 2018
Professional fees	$	171,474	$	269,544
Payroll and other employee-related costs	48,797		417,997
Consumer product-related costs	10,481		5,360
Restructuring-related costs	—		68,593
Other research and development-related costs	—		2,846
Total	$	230,752	$	764,340

Schedule of Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:



	June 30, 2019		December 31, 2018
Professional fees	$	171,474	$	269,544
Payroll and other employee-related costs	48,797		417,997
Consumer product-related costs	10,481		5,360
Restructuring-related costs	—		68,593
Other research and development-related costs	—		2,846
Total	$	230,752	$	764,340

Restructuring and Related Costs

The following table outlines the Company's restructuring activities for the six months ended June 30, 2019:



Accrued restructuring balance as of December 31, 2018	$	68,593
Adjustments:
Employee termination benefits	(11,228		)
Payments	(57,365		)
Accrued restructuring balance as of June 30, 2019	$	—

Common stock (Tables)

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Restricted Common Stock Activity

The following is a summary of restricted common stock activity:



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2018	2,084		$	11.05
Issued	—		—
Vested	(1,250	)	11.05
Forfeited	—		—
Unvested at June 30, 2019	834		$	11.05

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Summary of Stock Option Activity

The following table summarizes stock option activity for employees and non-employees for the six months ended June 30, 2019:



	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2018	2,320,981		$	4.10	7.61	$	—
Granted	—		—
Exercised	—		—
Forfeited	—		—
Expired	(23,945	)	4.41
Outstanding at June 30, 2019	2,297,036		$	4.10	7.11	$	—
Exercisable at June 30, 2019	1,346,425		$	5.11	6.05	$	—
Vested or expected to vest at June 30, 2019	2,297,036		$	4.10	7.11	$	—

Summary of Stock-based Compensation Expense



	Three Months Ended June 30, 2019		Three Months Ended June 30, 2018		Six Months Ended June 30, 2019		Six Months Ended June 30, 2018
Research and development	$	19,323	$	244,869	$	38,765	$	631,406
Selling, general and administrative	193,224		266,124		394,757		788,527
Total	$	212,547	$	510,993	$	433,522	$	1,419,933

Net loss per share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share



	June 30, 2019	June 30, 2018
Options to purchase common stock	2,297,036	3,098,813
Unvested restricted common stock	834	3,334
Total	2,297,870	3,102,147

Segment Information (Tables)

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Schedule Of Information For The Company's Operating Segments

Information for the Company's reportable segments for the three months ended June 30, 2019 and 2018 are as follows:



Three Months Ended June 30, 2019	Consumer Operations		Drug Development		Corporate		Consolidated
Total revenue	$	164,705	—		—		$	164,705
Interest income, net	$	—	—		13,361		$	13,361
Income (loss) from operations	$	11,821	(29,294	)	(1,380,665	)	$	(1,398,138	)



Three Months Ended June 30, 2018	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	245,502		—		—		$	245,502
Interest income, net	$	—		—		51,809		$	51,809
Loss from operations	$	(645,687	)	(6,170,488	)	(2,287,506	)	$	(9,103,681	)

Information for the Company's reportable segments for the six months ended June 30, 2019 and 2018 are as follows:



Six Months Ended June 30, 2019	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	269,682		—		—		$	269,682
Interest income, net	$	—		—		26,574		$	26,574
Loss from operations	$	(41,287	)	(29,678	)	(3,570,816	)	$	(3,641,781	)



Six Months Ended June 30, 2018	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	424,084		—		—		$	424,084
Interest income, net	$	—		—		111,402		$	111,402
Loss from operations	$	(1,902,993	)	(10,834,565	)	(4,648,943	)	$	(17,386,501	)

Organization and operations (Details)	3 Months Ended				6 Months Ended
Organization and operations (Details)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2019 USD ($) segment	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments \| segment					2
Net loss	$ 1,384,777	$ 2,230,430	$ 9,051,872	$ 8,223,227	$ 3,615,207	$ 17,275,099
Retained earnings (accumulated deficit)	(136,576,482)				(136,576,482)		$ (132,961,275)
Cash and cash equivalents	$ 6,514,215				$ 6,514,215		$ 9,829,624

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Summary of significant accounting policies and recent accounting pronouncements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Advertising expense	$ 8,000	$ 264,000	$ 18,000	$ 772,000
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of product revenue	36,148	179,945	83,477	263,879
Shipping and Handling
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of product revenue	$ 20,000	$ 29,000	$ 35,000	$ 54,000

Revenue from contracts with customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended			9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 18, 2018	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Refund period					30 days	14 days
Discounts to customers	$ 1	$ 9	$ 2	$ 17

Fair value measurements (Details) - Fair Value, Measurements, Recurring - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 2,360,092	$ 2,333,771
Total assets	2,360,092	2,333,771
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,360,092	2,333,771
Total assets	2,360,092	2,333,771
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total assets	$ 0	$ 0

Cash equivalents (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash and Cash Equivalents [Abstract]
Marketable securities	$ 0	$ 0
Cash and cash equivalents	6,514,215	9,829,624
Restricted cash	0	126,595
Cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$ 6,514,215	$ 9,956,219	$ 15,883,566	$ 19,312,631

Inventory (Details) - USD ($)	3 Months Ended		6 Months Ended
Inventory (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 7,247		$ 7,247		$ 7,247
Finished goods	123,673		123,673		179,673
Total inventory	130,920		130,920		$ 186,920
Write-off of inventory	$ 0	$ 85,000	$ 0	$ 85,000

Accrued expenses and other current liabilities - Summary of accrued expenses and other current liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Professional fees	$ 171,474	$ 269,544
Payroll and other employee-related costs	48,797	417,997
Consumer product-related costs	10,481	5,360
Restructuring-related costs	0	68,593
Other research and development-related costs	0	2,846
Total	$ 230,752	$ 764,340

Accrued expenses and other current liabilities - Narrative (Details)	1 Months Ended	3 Months Ended	6 Months Ended	13 Months Ended
	Jun. 30, 2018	Jun. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2019 USD ($) employee
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)		$ 0	$ (11,000)	$ 1,765,000
Number of retained employees \| employee				7
One-time termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)			3,000	$ 97,000
Termination and retention benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				1,355,000
Ongoing termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)			8,000	1,029,000
Employee retention benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				214,000
Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				15,000
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)			(11,000)	957,000
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				808,000
Consumer Operations
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				94,000
Drug Development
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)			(11,000)	957,000
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				714,000
Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				1,765,000
Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				3,343,000
Maximum \| Consumer Operations
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				114,000
Maximum \| Drug Development
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				1,024,000
Maximum \| Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credit)				2,205,000
Corporate restructuring plan, cost structure reduction
Restructuring Cost and Reserve [Line Items]
Percentage decrease in company workforce	60.00%
Retention bonus costs				51,000
Severance costs				889,000
Corporate restructuring plan, retention and severance increases
Restructuring Cost and Reserve [Line Items]
Retention bonus costs				214,000
Severance costs				185,000
Annual bonus cost				410,000
Cash retention bonuses payable		603,000	603,000	603,000
Severance benefits payable upon change in control and termination without cause		$ 928,000	$ 928,000	$ 928,000

Accrued expenses and other current liabilities - Summary of restructuring reserve activity (Details) - USD ($)	3 Months Ended	6 Months Ended	13 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019
Restructuring Reserve [Roll Forward]
Accrued restructuring balance as of December 31, 2018		$ 68,593
Adjustments: Employee termination benefits	$ 0	(11,000)	$ 1,765,000
Payments		(57,365)
Accrued restructuring balance as of June 30, 2019	$ 0	0	$ 0
Employee termination benefits
Restructuring Reserve [Roll Forward]
Adjustments: Employee termination benefits		$ (11,228)

Common stock - Narrative (Details)	6 Months Ended	12 Months Ended
Common stock - Narrative (Details)	Jun. 30, 2019 vote $ / shares shares	Dec. 31, 2016 shares	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)	100,000,000		100,000,000
Common stock, par value (in usd per share) \| $ / shares	$ 0.0001		$ 0.0001
Common stock, number of votes per share \| vote	1
Restricted stock \| Non-employee Consultants and Advisers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock, shares sold (shares)		18,194
Restricted common stock, shares outstanding (shares)	17,360

Common stock - Restricted common stock activity (Details) - Restricted stock - Non-employee Consultants and Advisers	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Number of Shares
Beginning balance, unvested (shares) \| shares	2,084
Issued (shares) \| shares	0
Vested (shares) \| shares	(1,250)
Forfeited (shares) \| shares	0
Ending balance, unvested (shares) \| shares	834
Weighted-Average Grant Date Fair Value
Beginning balance, weighted average grant date fair value (in usd per share) \| $ / shares	$ 11.05
Issued, weighted average grant date fair value (in usd per share) \| $ / shares	0.00
Vested, weighted average grant date fair value (in usd per share) \| $ / shares	11.05
Forfeited, weighted average grant date fair value (in usd per share) \| $ / shares	0.00
Ending balance, weighted average grant date fair value (in usd per share) \| $ / shares	$ 11.05

Stock-based compensation - Narrative (Details)		6 Months Ended
Stock-based compensation - Narrative (Details)	Jun. 14, 2018 employee shares	Jun. 30, 2019 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period (in years)	48 months
Unrecognized compensation cost \| $		$ 1,726,000
Unrecognized compensation cost, recognition period (in years)		2 years 4 months 6 days
Number of stock options granted (shares)	654,544	0
Number of employees granted options \| employee	7
Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, contractual term		10 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, post termination exercisability extended period	1 year
Minimum \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period (in years)		1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, post termination exercisability extended period	3 years
Maximum \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period (in years)		4 years
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remaining available for grant of stock awards (shares)		2,487,140

Stock-based compensation - Summary of stock option activity (Details) - USD ($)		6 Months Ended	12 Months Ended
	Jun. 14, 2018	Jun. 30, 2019	Dec. 31, 2018
Shares
Shares outstanding, Beginning Balance (shares)		2,320,981
Shares granted (shares)	654,544	0
Shares exercised (shares)		0
Shares forfeited (shares)		0
Shares expired (shares)		(23,945)
Shares outstanding, Ending Balance (shares)		2,297,036	2,320,981
Shares exercisable (shares)		1,346,425
Shares vested or expected to vest (shares)		2,297,036
Weighted-Average Exercise Price
Shares outstanding, weighted-average exercise price, Beginning Balance (in usd per share)		$ 4.10
Shares granted, weighted-average exercise price (in usd per share)		0.00
Shares exercised, weighted-average exercise price (in usd per share)		0.00
Shares forfeited, weighted-average exercise price (in usd per share)		0.00
Shares expired, weighted-average exercise price (in usd per share)		4.41
Shares outstanding, weighted-average exercise price, Ending Balance (in usd per share)		4.10	$ 4.10
Shares exercisable, weighted-average exercise price (in usd per share)		5.11
Shares vested or expected to vest, weighted-average exercise price (in usd per share)		$ 4.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, weighted-average remaining contractual term (in years)		7 years 1 month 10 days	7 years 7 months 10 days
Exercisable, weighted-average remaining contractual term (in years)		6 years 18 days
Vested or expected to vest, weighted-average remaining contractual term (in years)		7 years 1 month 10 days
Outstanding, aggregate intrinsic value		$ 0	$ 0
Exercisable, aggregate intrinsic value		0
Vested or expected to vest, aggregate intrinsic value		$ 0

Stock-based compensation - Summary of stock-based compensation expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Service Share-Based Compensation Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 212,547	$ 510,993	$ 433,522	$ 1,419,933
Research and development
Employee Service Share-Based Compensation Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	19,323	244,869	38,765	631,406
Selling, general and administrative
Employee Service Share-Based Compensation Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 193,224	$ 266,124	$ 394,757	$ 788,527

Income taxes (Details) - USD ($)	6 Months Ended
Income taxes (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income tax provision (benefit)	$ 0	$ 0

Net loss per share (Details) - shares	6 Months Ended
Net loss per share (Details) - shares	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	2,297,870	3,102,147
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	2,297,036	3,098,813
Unvested restricted common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	834	3,334

Segment Information (Details)	3 Months Ended		6 Months Ended
Segment Information (Details)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) segment	Jun. 30, 2018 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			2
Segment Reporting Information [Line Items]
Total revenue	$ 164,705	$ 245,502	$ 269,682	$ 424,084
Interest income, net	13,361	51,809	26,574	111,402
Income (loss) from operations	(1,398,138)	(9,103,681)	(3,641,781)	(17,386,501)
Operating Segments \| Consumer Operations
Segment Reporting Information [Line Items]
Total revenue	164,705	245,502	269,682	424,084
Interest income, net	0	0	0	0
Income (loss) from operations	11,821	(645,687)	(41,287)	(1,902,993)
Operating Segments \| Drug Development
Segment Reporting Information [Line Items]
Total revenue	0	0	0	0
Interest income, net	0	0	0	0
Income (loss) from operations	(29,294)	(6,170,488)	(29,678)	(10,834,565)
Corporate
Segment Reporting Information [Line Items]
Total revenue	0	0	0	0
Interest income, net	13,361	51,809	26,574	111,402
Income (loss) from operations	$ (1,380,665)	$ (2,287,506)	$ (3,570,816)	$ (4,648,943)

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 40,217
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 40,217